Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport vs Xeomin for Overactive Bladder and Urge Urinary Incontinence
NCT06250543Phase 4Completed
- Start
- Aug 2018
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of botulinum toxin type A in overactive bladder (OAB) and urge urinary incontinence (UUI). Started Aug 2018; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)urge urinary incontinence (UUI)
Beyond the preview
Go deeper on NCT06250543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06250543.